Elevated epiregulin expression predicts poor prognosis in gastric cancer.

[1]  Yan Zhou,et al.  Abnormal amphiregulin expression correlates with gastric cancer prognosis , 2016, Oncotarget.

[2]  Zhenqing Feng,et al.  Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. , 2016, American journal of cancer research.

[3]  Yan Zhou,et al.  Trop2 is overexpressed in gastric cancer and predicts poor prognosis , 2015, Oncotarget.

[4]  N. Sunaga,et al.  Epiregulin as a therapeutic target in non-small-cell lung cancer , 2015, Lung Cancer.

[5]  Weizhi Wang,et al.  The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population , 2015, OncoTarget.

[6]  Nayoung Kim,et al.  Diagnosis and Management of High Risk Group for Gastric Cancer , 2015, Gut and liver.

[7]  W. Wang,et al.  Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues , 2014, Oncotarget.

[8]  F T Bosman,et al.  Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Lei Wang,et al.  Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma. , 2014, Neuro-oncology.

[10]  D. Riese,et al.  Epiregulin: roles in normal physiology and cancer. , 2014, Seminars in cell & developmental biology.

[11]  P. Leung,et al.  EGF-like growth factors induce COX-2-derived PGE2 production through ERK1/2 in human granulosa cells. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  Shi‐Xu Jiang,et al.  The clinicopathological significance of Lgr5 expression in lung adenocarcinoma. , 2013, Lung cancer.

[13]  J. Minna,et al.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer , 2013, Oncogene.

[14]  T. Joh,et al.  A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies , 2013, Journal of Cancer Research and Clinical Oncology.

[15]  A. Levine,et al.  LGR5‐Positive Colon Cancer Stem Cells Interconvert with Drug‐Resistant LGR5‐Negative cells and are Capable of Tumor Reconstitution , 2012, Stem cells.

[16]  I. Wistuba,et al.  HER family receptor and ligand status in thymic carcinoma. , 2012, Lung cancer.

[17]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[18]  J. Wennerberg,et al.  Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines , 2012, Journal of Cancer Research and Clinical Oncology.

[19]  E. Shezen,et al.  Epiregulin as a marker for the initial steps of ovarian cancer development. , 2011, International journal of oncology.

[20]  T. Ishikawa,et al.  Activation of epidermal growth factor receptor signaling by the prostaglandin E2 receptor EP4 pathway during gastric tumorigenesis , 2011, Cancer science.

[21]  Yoko Yamamoto,et al.  Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. , 2010, European journal of cancer.

[22]  Colin G. Johnson,et al.  The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer , 2010, Breast Cancer Research and Treatment.

[23]  Y. Shu,et al.  Amphiregulin and Epiregulin Expression in Colorectal Carcinoma and the Correlation with Clinicopathological Characteristics , 2010, Oncology Research and Treatment.

[24]  Li Liu,et al.  Elevated expression of mature miR-21 and miR-155 in cancerous gastric tissues from Chinese patients with gastric cancer , 2010, Journal of biomedical research.

[25]  J. Vandesompele,et al.  Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Shao,et al.  Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. , 2009, Biochemical and biophysical research communications.

[27]  Y. Yamashita,et al.  Up‐regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands , 2009, Cancer science.

[28]  Cun-Yu Wang,et al.  Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. , 2009, Oral oncology.

[29]  Jie Zhang,et al.  Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells , 2008, Cancer Prevention Research.

[30]  Y. Mitani,et al.  Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. , 2008, Oncology reports.

[31]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Goya,et al.  Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  M. Conti,et al.  Role of the Epidermal Growth Factor Network in Ovarian Follicles the Physiology of Follicle Maturation and Ovulation , 2022 .

[34]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[35]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[36]  H. Frierson,et al.  Profiling the Evolution of Human Metastatic Bladder Cancer , 2004, Cancer Research.

[37]  M. Kurosaka,et al.  Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. , 2004, Anticancer research.

[38]  S. Poulsen,et al.  A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. , 2001, Cancer research.

[39]  H. Friess,et al.  Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. , 2000, Biochemical and biophysical research communications.

[40]  Y. Yarden,et al.  Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes* , 1998, The Journal of Biological Chemistry.

[41]  D. Uchida,et al.  Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4 , 1997, Oncogene.

[42]  D. Uchida,et al.  Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. , 1997, The Biochemical journal.

[43]  W. Wu,et al.  Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. , 2009, Anticancer research.

[44]  F. Révillion,et al.  ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  N. Tørring,et al.  Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. , 2000, Anticancer research.